Monitor for continuity in financial strategy and investor communications. The reiteration of guidance suggests stability, but the combination of a CFO change and recent proxy fight warrants scrutiny of upcoming financial reports for any deviations from stated projections.
Price Chart
Executive Summary
Harmony Biosciences announced the departure of CFO Sandip Kapadia and the immediate appointment of Glenn Reicin as his replacement. The company reiterated its 2026 net revenue guidance of $1.0–1.04 billion. This leadership transition follows a recent proxy fight, suggesting ongoing board-level tensions.
Key Facts
- CFO Sandip Kapadia stepped down effective April 14, 2026, after serving since 2021
- Glenn Reicin appointed as new CFO effective immediately, with a $500,000 base salary and $3 million option grant
- Kapadia's separation agreement includes $539,000 severance and accelerated vesting of October 2023 equity awards
- Company reaffirmed 2026 net revenue guidance of $1.0–1.04 billion
- This change follows a contested 2026 proxy election, indicating potential governance tensions
Financial Impact
Approximately $3.5 million in total separation and onboarding costs (severance, equity acceleration, and new hire grant)
Risk Factors
- Potential disruption during CFO transition
- Ongoing governance tensions following contested proxy vote
- Execution risk if new CFO alters capital allocation strategy
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-042886 |
| Document: hrmy-20260414xex10d2.htm | 0001104659-26-042886 |
| Document: hrmy-20260414x8k.htm | 0001104659-26-042886 |
| Document: hrmy-20260414xex99d1.htm | 0001104659-26-042886 |
| Document: 0001104659-26-042886-index-headers.html | 0001104659-26-042886 |
| Document: 0001104659-26-042886-index.html | 0001104659-26-042886 |
| Document: 0001104659-26-042886.txt | 0001104659-26-042886 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $38.78 $39.52 | ▲ +1.91% | ▲ +2.01% | $40.53 (+4.53%) |
Aug 4, 2026 8w ago | Press Release | $38.78 $39.52 | ▲ +1.91% | ▲ +2.01% | $40.53 (+4.53%) |
Jul 16, 2026 11w ago | 8-K | $33.53 $35.80 | ▲ +6.77% | ▲ +8.44% | $40.53 (+20.89%) |
Jun 30, 2026 13w ago | 144 | $36.00 $38.26 | ▼ −6.28% | ▼ −6.02% | $40.53 (−12.60%) |
Jun 24, 2026 14w ago | 144 | $34.13 $36.00 | ▼ −5.48% | ▼ −3.92% | $40.53 (−18.77%) |
Jun 9, 2026 16w ago | 144 | $35.48 $33.83 | ▼ −4.65% | ▼ −8.08% | $40.53 (+14.25%) |
Jun 5, 2026 16w ago | 144 | $32.39 $34.18 | ▲ +5.53% | ▲ +3.41% | $40.53 (+25.15%) |
May 19, 2026 19w ago | 3 | $30.44 $30.76 | ▲ +1.05% | ▼ −1.25% | $40.53 (+33.16%) |
May 7, 2026 21w ago | 8-K | $31.42 $30.83 | ▼ −1.88% | ▼ −3.38% | $40.53 (+29.01%) |
Apr 14, 2026 24w ago | 8-K | $29.29 $32.14 | ▲ +9.73% | ▲ +8.34% | $40.53 (+38.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access